AstraZeneca and Daiichi Sankyo’s Enhertu Receives U.S. Priority Review for Early HER2-Positive Breast Cancer
AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration granted Priority Review for Enhertu as a post-neoadjuvant treatment for patients with HER2-positive early breast cancer who have residual disease after initial therapy. The application is supported by results from the Phase 3 DESTINY-Breast05 trial, which showed the antibody-drug conjugate significantly improved invasive disease-free survival compared with the current standard therapy.
AstraZeneca and Daiichi Sankyo’s Enhertu Receives U.S. Priority Review for Early HER2-Positive Breast Cancer